Updated:
ALX Oncology Limited
ALX Oncology Limited is based in Burlingame; the profile covers headquarters, registration, AUM band and key contacts for private-markets fundraising.
Overview
We’re dedicated to expanding the possibilities for patients by developing novel approaches to optimize current and future standards of care.
General information
Location
Region
North America
Country
United States
City
Burlingame
Corporate office
323 Allerton Avenue, South San Francisco, CA 94080, United States
Sector focus
Frequently asked questions
Who leads ALX Oncology?
ALX Oncology's leadership team is composed of experienced drug developers; specific named executives are not captured in available sources. The company is publicly traded (NASDAQ: ALXO) and discloses management in SEC filings (per SEC, 2024).
What is evorpacept and how does it differ from other CD47 inhibitors?
Evorpacept is ALX Oncology's lead therapeutic candidate, a high-affinity SIRPα-Fc fusion protein that blocks the CD47 'don't eat me' signal on cancer cells. It is engineered to reduce the anemia commonly associated with earlier CD47 antibodies, such as those from Forty Seven (per ALX Oncology, 2025).
What clinical stages is evorpacept in?
As of 2025, evorpacept is in Phase 2 and Phase 1/2 clinical trials across multiple indications, including B-cell non-Hodgkin lymphoma (NCT05894174), head and neck squamous cell carcinoma, and acute myeloid leukemia (per clinicaltrials.gov, 2025). The firm has not yet received FDA approval for any candidate.
Does ALX Oncology rely solely on internal capital or seek partnerships?
ALX Oncology has funded its operations through public equity offerings and, in December 2023, announced a strategic collaboration with Coherus BioSciences to evaluate evorpacept in combination with toripalimab (per SEC, 2023). The firm partners with larger biopharmas for co-development.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: